Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer

Laura J. Havrilesky, Robin Pokrzywinski, Dennis Revicki, Robert V. Higgins, Lawrence R. Nycum, Matthew F. Kohler, Andrew Berchuck, Evan R. Myers, Angeles Alvarez Secord

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

BACKGROUND: In a randomized controlled trial (RCT) of patients with recurrent, platinum-sensitive ovarian cancer, the combination weekly docetaxel and carboplatin was associated a with progression-free survival (PFS) of 13.7 months compared with 8.4 months for sequential, single-agent docetaxel followed by carboplatin. The objective of the current study was to construct a cost-utility model to compare these 2 regimens with the incorporation of prospectively collected quality-of-life (QoL) data. METHODS: An RCT of concurrent docetaxel and carboplatin (cDC) versus docetaxel followed by carboplatin (sequential docetaxel and carboplatin [sDC]) was the basis for a Markov decision model, and the primary effectiveness outcome was PFS. Costs were estimated using US dollars based on Medicare reimbursements for chemotherapy regimens, bone marrow support, and management of adverse events. QoL data obtained using the Functional Assessment of Cancer Therapy-General questionnaire were converted to utilities. Costs and incremental cost-effectiveness ratios (ICERs) were reported in US dollars per quality-adjusted life year (QALY). Extensive 1-way sensitivity analyses and a Monte Carlo probabilistic sensitivity analysis were performed. RESULTS: The least expensive strategy was sDC, which cost an average of $20,381, compared with cDC, which cost an average of $25,122. cDC had an ICER of $25,239 per QALY compared with sDC. cDC remained cost-effective, with an ICER <$50,000 per QALY, over a range of costs and estimates. In Monte Carlo sensitivity analysis using a $50,000 per QALY willingness-to-pay threshold, cDC was either dominant or cost-effective with an ICER <$50,000 per QALY in 83% of simulations. CONCLUSIONS: Combined weekly cDC appeared to be cost-effective compared with sDC as treatment strategy for patients with platinum-sensitive ovarian cancer, even when accounting for slightly lower QoL during treatment.

Original languageEnglish (US)
Pages (from-to)386-391
Number of pages6
JournalCancer
Volume118
Issue number2
DOIs
StatePublished - Jan 15 2012
Externally publishedYes

Keywords

  • Cost-effectiveness
  • Monte Carlo simulation
  • Ovarian cancer
  • Platinum-sensitive
  • Recurrent ovarian cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer'. Together they form a unique fingerprint.

  • Cite this

    Havrilesky, L. J., Pokrzywinski, R., Revicki, D., Higgins, R. V., Nycum, L. R., Kohler, M. F., Berchuck, A., Myers, E. R., & Secord, A. A. (2012). Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer. Cancer, 118(2), 386-391. https://doi.org/10.1002/cncr.26199